ストックスクリーナーアプリを入手
1.64
0.61%
0.01
前日終値:
$1.63
開ける：
$1.64
24時間の取引高:
614.58K
Relative Volume:
0.90
時価総額：
$112.13M
収益：
$593.00K
当期純損益:
$-45.85M
株価収益率:
-2.3889
EPS:
-0.6865
ネットキャッシュフロー:
$-37.97M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
+3.80%
6か月 パフォーマンス:
-26.79%
1年 パフォーマンス:
-40.36%
1日の値動き範囲:
$1.61
$1.67
1週間の範囲:
$1.60
$1.705
52週間の値動き範囲:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.64 | 111.44M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | Noble Capital Markets | Outperform |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-06-24 | 開始されました | Jefferies | Hold |
| 2024-09-06 | 開始されました | Craig Hallum | Buy |
| 2022-01-05 | 開始されました | William Blair | Outperform |
| 2021-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-09 | 再開されました | Maxim Group | Buy |
| 2020-10-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - GlobeNewswire
Mayo Clinic leukemia expert joins Cardiff webinar on CMML drug data - Stock Titan
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
CRDF (Cardiff Oncology Inc.) reports narrower than expected Q4 2025 loss, shares climb 4.29% on positive investor sentiment.Buyback Report - Cổng thông tin điện tử tỉnh Lào Cai
Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com - Investing.com Nigeria
Cardiff Oncology to present colorectal cancer trial data at ASCO - Investing.com
Cardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026 - Quiver Quantitative
Updated metastatic colon cancer data gets ASCO oral slot - Stock Titan
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Sahm
Cardiff Oncology presents preclinical data on cancer drug combo By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AA - GuruFocus
Cardiff Oncology presents preclinical data on cancer drug combo - Investing.com
Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options - Stock Titan
Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036 - Stock Titan
Cardiff Oncology (CRDF) CFO receives 486,650 options at $1.58 strike - Stock Titan
Cardiff Oncology | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Muntner Joshua Bmoomoo - Moomoo
Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
大文字化:
|
ボリューム (24 時間):